医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Sol-Millennium Responds to FDA’s Warning Letter and Safety Communication

2024年03月22日 AM07:10
このエントリーをはてなブックマークに追加


 

CHICAGO

Sol-Millennium, manufacturer of medical devices, including syringes for medicine delivery and testing, issued a statement regarding March 19th update to the FDA’s Safety Communication (“Evaluating Plastic Syringes Made in China for Potential Device Failures”) and a Warning Letter to Sol-Millennium.

After multiple communications with the FDA, we are confident that all the issues can be resolved.

Since November 2023, Sol-Millennium has been providing reports of actions it has taken to address any findings identified in the Warning Letter. These are regulatory in nature.

The principal focus of the Warning Letter is on our 510(k) and whether our “combination” products (needle + syringe attached) constitute a significant change or modification in design that could significantly alter the safety and effectiveness of the devices. The 510(k) for our needle and the 510(k) for our syringe as separate items are not in question by the FDA. We are in the process of submitting applications for premarket clearance for the combination product to address this observation. For the needle and the syringe combination products, we offer them separately (unattached) under our own cleared Sol-Millenniums’ 510(k)s.

Since September 2023, the FDA has inspected approximately one third of Sol-Millennium’s inbound shipments into the United States, including multiple lab tests, and has had zero quality concerns.

Sol-Millennium has no relationship with Jiangsu Caina Medical Co Ltd, and Jiangsu Shenli Medical Production Co Ltd. These are the two manufacturers cited in the FDA’s Safety Communication Letter that the FDA recommends to “Immediately transition away from using plastic syringes manufactured” by these manufactures… “[because of] potential quality and performance issues”. No Sol-Millennium products are manufactured by either company.

Sol-Millennium puts product safety and reliability as its top priority. Our devices undergo rigorous design and development processes to ensure they meet globally recognized ISO standards including ISO 7886-1:2017, ISO 7886-2:2020, ISO 8537:2016, ISO 7864:2016, and ISO 9626:2016 for their medical device portfolio.

For more information, please contact Sol-Millennium at info@sol-m.com.

Sol-Millennium Medical Group is one of the world’s largest manufacturers of needles and syringes that provided 2 billion needles and syringes in global pandemic response. It is vertically integrated with locations across the globe. Sol-Millennium’s innovative technology enhances both clinician and patient experience. With an international sales team dedicated to delivering knowledge and outstanding customer service, Sol-Millennium’s mission is building a healthier tomorrow.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240321003462/en/

CONTACT

info@sol-m.com

同じカテゴリーの記事 

  • ReNAgade Therapeutics继续致力于GanNA Bio和糖生物学的研究
  • ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology
  • C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer’s Disease and Brain Research Market
  • BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
  • Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer